Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
endometrial cancer, VEGF(R) inhibitor vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-775, 2023 0.65 [0.55; 0.77]
0.65 [0.55 ; 0.77 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable PFS (extension)detailed results KEYNOTE-775, 2023 0.56 [0.48; 0.66]
0.56 [0.48 ; 0.66 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable progression or deaths (PFS)detailed results KEYNOTE-775, 2023 0.56 [0.47; 0.66]
0.56 [0.47 ; 0.66 ] KEYNOTE-775, 2023 1 0% NA not evaluable objective responses (ORR)detailed results KEYNOTE-775, 2023 2.97 [2.12; 4.18]
2.97 [2.12 ; 4.18 ] KEYNOTE-775, 2023 1 0% 827 NA not evaluable AE (any grade)detailed results KEYNOTE-775, 2023 2.10 [0.19; 23.24]
2.10 [0.19 ; 23.24 ] KEYNOTE-775, 2023 1 0% 794 NA not evaluable AE (grade 3-5)detailed results KEYNOTE-775, 2023 3.26 [2.19; 4.85]
3.26 [2.19 ; 4.85 ] KEYNOTE-775, 2023 1 0% 794 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-775, 2023 7.41 [4.88; 11.26]
7.41 [4.88 ; 11.26 ] KEYNOTE-775, 2023 1 0% 794 NA not evaluable SAE (any grade)detailed results KEYNOTE-775, 2023 2.94 [2.20; 3.94]
2.94 [2.20 ; 3.94 ] KEYNOTE-775, 2023 1 0% 794 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-27 13:04 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 77,383
- treatments: 776,1069,693,1068,900,1084,1016,1323,985,604,1014,1447,1476,1477,777,1027,1028,669,1564,670,1015,1023,506,908